-Eli Lilly and Co said on Thursday it had received a subpoena from the U.S. Department of Justice related to its New Jersey plant that makes its COVID-19 treatment, bamlanivimab.. | May 27, 2021
INDIANAPOLIS, May 22, 2021 /PRNewswire/ In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company s mirikizumab improved fatigue in patients with moderately to severely. | May 22, 2021
Up 48.38% from 52 weeks ago (March 16, 2020), when it closed at $129.38 Down 9.75% from its 52-week closing high of $212.72 on Jan. 26, 2021 Up 61.26% from its 52-week closing low of $119.05 on March 23, 2020 Traded as low as $189.48; lowest intraday level since Jan. 15, 2021, when it hit $186.80 Down 8.94% at today s intraday low; largest intraday percent decrease since March 20, 2020, when it fell as much as 9.66% Worst performer in the S&P 500 today All data as of 10:13:51 AM Source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires
By Colin Kellaher Eli Lilly & Co. on Friday said the European Medicines Agency s Committee for Medicinal Products for Human Use issued a positive scientific opinion for the company s antibody-based Covid-19 drugs aimed at helping people at high risk of severe disease avoid hospitalization. The Indianapolis drugmaker said the opinion covers its monoclonal antibody bamlanivimab alone and in combination with one named etesevimab for the treatment of confirmed Covid-19 in patients ages 12 years and older who don t need supplemental oxygen and are at high risk of progressing to severe Covid-19. Monoclonal antibodies are engineered proteins that mimic the immune system s ability to fight off viruses.